Successful UK IDAP Application by Histosonics supported by Device Access UK results in NHS adoption.

Successful UK IDAP Application by Histosonics supported by Device Access UK results in NHS adoption.
 
Device Access UK are delighted to announce that following their client Histosonics Inc, having been successfully selected by the UK Governments Innovative Devices Access Pathway is now being offered to NHS patients
 
Only 8 technologies were shortlisted and selected by this UK Government initiative to allow technologies to be accelerated through a brand new fast-track regulatory and market access programme, which means that NHS Patients in the UK will be able to benefit from Histosonics non-invasive, sonic beam therapy platform that uses histotripsy, which is capable of destroying targeted liver tumors at a sub-cellular level.
 
Device Access UK helped Histosonics understand the current care pathways for NHS liver cancer patients, they did this by analysing their licensed Hospital Episode Statistics (HES) datasets, showing how a completely novel approach could potentially free up thousands of NHS beds and facilities currently utilised, thus aligning to requirements of the IDAP program needs of transforming care.
 
UK Government said in their press release “NHS patients will be the first in Europe to benefit from a ground-breaking, non-invasive liver cancer treatment, as the Government’s Plan for Change slashes burdensome red tape and drives innovation, establishing Britain’s role as a medical technology powerhouse.”
Using ultrasound technology, the device – developed by US-based company HistoSonics – destroys tumours without surgery, scalpels, radiation, with minimal damage to surrounding organs.
Patients stand to benefit from faster recovery times, potentially greater survival rates, fewer potentially dangerous complications, and less hospital stays – helping to cut waits for others – all marking a new era in cancer treatment.

It’s a major step forward for patients with liver cancer and shows how the UK can be a frontrunner in supporting responsible innovation that meets real clinical need.
Josh King VP Global Market Access at HistoSonics said “Collaborating with the Device Access team was extremely helpful in aligning the innovative benefits of histotripsy’s non-invasive treatment of liver tumours to the UK’s impressive mission of improving healthcare for the diverse patient population across the entire health system. "
 
John West, Chief Commercial officer of Device Access UK Ltd said “For many years we have been supporting technology companies from both the UK and across the globe enter into the UK Healthcare system, from the very start we initially saw Edison(R) as a technology that will completely transform care and help the NHS at a time when technology is needed more than ever. We are truly delighted to have helped Histosonics on this Journey to bring this technology to NHS patients”